A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was 'do all patients with prosthetic valve endocarditis need surgery?' Seventeen papers were found using the reported search that represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. These studies compared the outcome and survival between surgically and non-surgically treated patients with prosthetic valve endocarditis. Of these studies, two were prospective observational studies and the rest were retrospective studies. The results of most of these papers were in accordance with the guidelines of the American College of Cardiology and American Heart association. These studies showed that unless a patient is not a surgical candidate, an operation is the treatment of choice in prosthetic valve endocarditis. Surgery should be performed as soon as possible, particularly in haemodynamically unstable patients and those who develop complications such as heart failure, valvular dysfunction, regurgitation/obstruction, dehiscence and annular abscess. In addition to the above indications and cardiac/valvularrelated complications of prosthetic valve endocarditis, infection with Staphylococcus aureus plays an important role in the outcome, and the presence of this micro-organism should be considered an urgent surgical indication in the treatment of prosthetic valve endocarditis. Surgery should be performed before the development of any cerebral or other complications. In contrast, in stable patients with other micro-organisms, particularly those with organisms sensitive to antibiotic treatment who have no structural valvular damage or cardiac complications, surgery can be postponed. The option of surgical intervention can also be revisited if there is a change in response to the treatment. This option is reserved for selected patients only and we conclude that as soon as the diagnosis of prosthetic valve endocarditis is made, cardiac surgeons should be involved.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A surgical review has been requested for a 73-year old man with diabetes, renal failure and a previous stroke who had a mechanical aortic valve replacement 15 years ago. The patient was admitted with septicaemia and investigations confirmed endocarditis of the mechanical prosthesis associated with moderate aortic regurgitation. He has been started on broad-spectrum antibiotics and surgical intervention needs to be considered. A redo aortic valve replacement is considered high risk and you decide to check the literature yourself before reaching a decision. Overall mortality with antibiotics only was higher compared with surgery, however, this significance was due to S. aureus PVE Mortality at 4 months (P < 0.05);
SEARCH STRATEGY
• Non-surgical = 48%
• Surgical = 25% Mortality in S. aureus group (P < 0.05)
• Non-surgical = 100%
• Surgical = 55% Mortality in non-S. aureus (P = NS)
• Non-surgical = 81%
• Surgical = 89% Mortality was significantly higher in non-surgical group
In-hospital mortality (P < 0.05)
Surgical group were younger, had lower American Society of Anaesthesia grade Study population was collected for a 20-year period but no difference in the study outcome at the beginning and end of the study was found Significantly better outcome with surgery in short-and long-term PVE = 1% 30-day mortality (P < 0.05)
• Non-surgical = 35%
• Surgical = 8% 1-year mortality (P < 0.05)
• Non-surgical = 60%
• Surgical = 26% 2-year mortality (P < 0.05) Almost half of the patients in the non-surgical group were too sick to be offered surgery which influences the survival data Decreased trend of PVE over the recent years • Non-surgical = 63%
Continued
• Surgical = 35% 3-year mortality (P < 0.05)
• Non-surgical = 67%
• Surgical = 39% Akowuah et al. [11] , 2003, Heart Retrospective (level III) 66 PVE; 28 non-surgical, 38 surgical
Better outcome with surgery but some selected patients can be treated with Abx alone PVE Incidence = 4.5% In-hospital mortality (P < 0.05)
• Non-surgical = 46%
• Surgical = 24% 10-year survival (P < 0.05)
• Non-surgical = 28%
• Surgical = 58% Freedom from endocarditis (P = NS)
• Non-surgical = 65%
• Surgical = 60% 29% in Abx group required surgery later In-hospital mortality (P = NS)
• Non-surgical = 42%
• Surgical = 26% 1-year survival (P < 0.05)
• Surgical = 71% In-hospital mortality (P = NS)
• Non-surgical = 30%
• Surgical = 26%
Micro-organism and heart failure rather than other complications Late PVE = 11% In-hospital mortality (P = NS)
• Non-surgical = 24%
S. aureus PVE should undergo surgery
Continued
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RESULTS
PVE is a serious condition and several factors influence the outcome. Based on the guidelines of the American College of Cardiology/American Heart Association, surgery is indicated for PVE resulting in haemodynamic instability, heart failure or valvular complications such as valve dysfunction/dehiscence, valvular obstruction/regurgitation or abscess formation (Class I). In persistent bacteraemia, relapsing infection and recurrent emboli, surgery is advisable (Class IIa). In cases of uncomplicated PVE with a sensitive organism, however, surgery is not indicated [2] . Our search showed that most studies published to date favour an aggressive approach to surgery for PVE. In 1986, a study by Calderwood et al. [3] confirmed that patients with complicated PVE do significantly better with surgery compared with those treated with antibiotics alone. In that study, surgery was mainly used to treat complicated PVE associated with Staphylococcus aureus infection. Yu et al. [4] and Otaki [5] also showed better survival with surgery, however, the groups were not comparable and high-risk patients who were not surgical candidates were included in the antibiotic therapy group. Wolf et al. reported their results focusing on infection with S. aureus. Their analysis showed no difference with medical or surgical treatment of patients with PVE with nonstaphylococcal organisms, whereas patients with S. aureus PVE had 100% mortality without surgery. They concluded that S. aureus PVE is the main predictor of outcome in PVE [6] . Similarly, Ho et al. [7] confirmed that surgery was more beneficial than medical therapy in S. aureus PVE. John et al. [8] and Sohail et al. [9] also reported the results of S. aureus PVE and showed significantly better outcome with surgery even in patients without valve-related complications.
In another study, 30-day, 1-and 3-year mortalities were shown to be significantly higher in a non-surgical group compared with those who had surgery, however, more than half of the patients in the non-surgical group were too ill to be operated on [10] . Ten-year survival was found to be significantly higher in the surgical group, but there was selection bias arising from the inclusion of non-surgical candidates in their analysis [11] . Other authors have shown better outcomes in these patients after 1 year when treated surgically, however, they failed to show any difference in the incidence of in-hospital mortality [12, 13] . In both of these studies, patients with valvular dysfunction were not included in the non-surgical category, and also conservative treatment was selected for patients with non-S. aureus PVE. Early onset of PVE was found to be more common with mechanical prostheses [12, 13] . Kuyvenhoven et al. [14] and López et al. [15] also showed no difference in the incidence of in-hospital mortality between treatment groups, but the type of micro-organism and the presence of heart failure were more important factors compared with other complications of PVE.
In contrast to the previous studies, Chirouze et al. showed that the overall mortality in S. aureus PVE was not different between the groups whether or not they had surgery. They included patients with heart failure in the surgical group and suggested that early surgery was only beneficial in patients with cardiac complications [16] . Tornos et al. studied late onset PVE and showed no difference between the groups with respect to in-hospital mortality, and 5-and 10-year survivals. They made a recommendation favouring early surgery for S. aureus PVE [17] . Truninger et al. also showed no difference in the mortality rate with or without surgery at mid-and long-term. His surgical group, however, included more patients with valvular complications whereas in his medical group, more patients with enterococcal PVE were included. He concluded that stable patients with non-staphylococcal PVE can be treated medically [18] .
Only 1 of the 17 studies demonstrated a worse outcome with surgery, however, the difference did not reach statistical Mortality at mid-term (P = NS)
• Non-surgical = 18%
• Surgical = 14% Mortality at long-term (P = NS)
• Non-surgical = 16%
• Surgical = 14% Need for reoperation (P = NS)
• Non-surgical = 19%
• Surgical = 14% In-hospital mortality (P = NS)
• Non-surgical = 14%
• Surgical = 35% 14% in non-surgical group required surgery at a later date Longer delay to diagnosis, more heart failure were seen in surgical group PVE: prosthetic valve endocarditis; ASA: American Society of Anesthesia; S. aureus: Staphylococcus aureus; CNS: central nervous system. significance. A longer delay in establishing the diagnosis and more heart failure in the surgical group were noted in this study as factors that negatively affect the outcome of surgery [19] .
CLINICAL BOTTOM LINE
Unless a patient is not a surgical candidate, in PVE, surgery is the treatment of choice. This is particularly the case in patients who develop complications as a result of PVE. These complications include heart failure, valvular dysfunction, valvular regurgitation or obstruction, valve dehiscence and annular abscess. In these patients, early surgery also improves the outcome and increases the survival.
Infection with S. aureus should be considered an indication for surgery in PVE even without cardiac or valvular complications. These patients should undergo surgery as soon as possible before cerebral complications develop. In patients with other microorganisms, especially where the organism is sensitive to the particular antibiotic treatment regime and no structural damage or cardiac complications have occurred, surgery can be postponed or reconsidered if there is response to the treatment. This option should be considered for selected patients only and cardiac surgeons should be involved from the early stages of the diagnosis.
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